Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Cancer Res. 2010 Oct 15;70(23):9827–9836. doi: 10.1158/0008-5472.CAN-10-1671

Figure 2.

Figure 2

PI3K/mTOR and MEK/ERK1/2 inhibition reduce viability of EML4-ALK-dependent lung cancer cells in vitro but not in vivo. A, H3122 cells were treated with the indicated concentrations of the MEK inhibitor AZD6244, the PI3K-mTOR inhibitor BEZ235, or the combination of both drugs. Cell viability was determined after 72 hours by MTS assay. Data are presented as the percentage of viable cells compared with untreated cells. B, H3122 cells were treated with indicated doses of AZD6244, BEZ235, or both for 14 days, and colonies counted. Bars denote SD. Student’s t tests were performed comparing PBS with AZD6244, BEZ235, or AZD/BEZ. *, P < 0.01, **, P < 0.001. C, H3122 cells were treated with PBS, AZD6244 (1 μmol/L), BEZ235 (0.2 μmol/L), or both for 6 hours. Lysates were subjected to Western blotting with the indicated antibodies, demonstrating expected effects on signal transduction by these compounds. D, EML4-ALK tumor-bearing mice were treated with the combination of AZD6244 and BEZ235. Tumor volumes were documented by MRI imaging. Mice were sacrificed after 2 weeks of treatment for pathologic analysis. Scale bar, 100 μm.